A5021279830- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- PI3K/AKT/mTOR signaling in cancer
- semigroups and automata theory
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- COVID-19 Clinical Research Studies
- BRCA gene mutations in cancer
- Chemotherapy-induced cardiotoxicity and mitigation
- Chronic Lymphocytic Leukemia Research
- Long-Term Effects of COVID-19
- Estrogen and related hormone effects
- Metabolism, Diabetes, and Cancer
- Vitamin C and Antioxidants Research
- DNA Repair Mechanisms
- Natural Language Processing Techniques
- DNA and Biological Computing
- Algorithms and Data Compression
City Clinical Oncology Center
2025
State Healthcare Institution "Regional Clinical Oncological Dispensary"
2024
St Petersburg University
2019-2024
Bashkir State Medical University
2022
Background. Given the high prevalence of hormone-sensitive breast cancer in Russia and around world, it is extremely important to address issue indications for neoadjuvant (NACT) or adjuvant chemotherapy, as well scope regimens treatment. The article presents results our own study, considers problems toxicity tolerability dose-dense standard NACT regimens. Aim. To study Materials methods. prospective included 109 patients. 53 patients received preoperative treatment, 56 – regimen. Results....
Background . Hyperglycemia (HG) is an on-target effect of ALP, and prophylactic with metformin was shown to decrease the rate severity HG. Here we present efficacy safety ALP in a large cohort patients rational approach usage based on risk factors Material Methods Patients (pts) HR+/HeR2- PIK3CA mut ABC were treated 300 mg orally FUL 500 IM until disease progression or intolerance. primary endpoints free survival (PFS) grade 3/4 HG different groups. Pts stratified groups algorithm before...
Background. By 2020, breast cancer (BC) has become the most frequent malignancy in world. The common type of BC is HR+/HER2-negative cancer,2540% which harbors PIK3CA mutations that affect catalytic subunit PI3K protein. alterations are actionable, as such neoplasms can be treated with a combination fulvestrant and inhibitor alpelisib. As have an extremely versatile effect on characteristics tumor cell, numerous associations various clinico-pathological traced.
 Aim. Our aim was to...
261,435,768 COVID-19 infections were detected worldwide, of them 5,207,634 deaths registered. Identifying markers the patient severity early in course disease can facilitate assessment risk adverse outcome. The objective: To compare values laboratory parameters and their changes during treatment patients with a complicated infection. Subjects Methods. 56 included study, all hospitalized to COVID Hospital Clinic Bashkir State Medical University, Russian Ministry Health, from September 30,...
e13053 Background: The data of ALP efficacy after FUL, chemotherapy (CT) and in later lines is limited. Only a small percentage pts BYLieve trial cohort C received FUL (32%), CT (37%) (only 4 4/4L+ lines). Therefore, we reported the real-world ALP+FUL with HR+/HER2−ABC PIK3CAm from initial year access Russian Federation. Methods: Pts HR+/HER2- ABC were treated 300mg QD orally 500mg IM until disease progression or intolerance. primary endpoints free survival (PFS) clinical benefit (CB)...
e13082 Background: The analysis of prescribing CDK4/6 inhibitors for patients with HR+/Her2neu- breast cancer was conducted at the St. Petersburg City Clinical Oncology Dispensary from April 2020 to October 2023. Patients in group 1 (n=365) received Palbociclib, and 2 (n=450) Ribociclib. Methods: 99.45% participants were female. In all average age both groups 66 years. Results: first line therapy, clinical oncologist's choice more often leaned towards Ribociclib (p=0.0293). later lines,...
Introduction. The presence of a germinal BRCA mutation occurs in 3–4% all breast cancer (BC) patients with various biological subtypes, but significantly high frequency triple negative subtype (in 10–20% cases). For the treatment HER2-negative metastatic associated gBRCA mutation, effectiveness biologically targeted drugs from group PARP inhibitors (olaparib and talazoparib) has been proven. P urpose. Comparison results our experience use talazoparib HER2-gBRCA+ + mBC data EMBRACA...
Triple-negative breast cancer (TNBC), while not the most frequent subtype, has a surprisingly aggressive course and low sensitivity to current antitumour drugs. Detection of predictive BRCA-mutation administration targeted therapy in first lines treatment metastatic TNRML can significantly affect life expectancy patients. The clinical case patient O. with BRCA-associated bilateral metachronous demonstrates how important it is implement personalised approach time. During patient’s treatment,...
1049 Background: Hyperglycemia (HG) is an on-target effect of ALP, and prophylactic with metformin was shown to decrease the rate severity HG. Here we present efficacy safety ALP in a large cohort patients rational approach usage based on risk factors Methods: Patients (pts) HR+/HER2- PIK3CAmut ABC were treated 300mg orally FUL 500mg IM until disease progression or intolerance. The primary endpoints free survival (PFS) grade 3/4 HG different groups. Pts stratified groups algorithm (table 1)...
The review is devoted to a new class of drugs - inhibitors cy-clin-dependent kinases. discovery the genetic and molecular mechanisms cell cycle regulation, as result, emergence CDK4 / 6 was breakthrough in treatment ER+ HER2- metastatic breast cancer changed paradigm hormone therapy this group patients. We consider current role treating patients with hormone-sensitive cancer, well prospects for future use drugs. article presents results main registration studies FDA-approved 6: palbocyclyb,...